LETTER
https://doi.org/10.1038/s41586-018-0517-0
Tracing HIV-1 strains that imprint broadly
neutralizing antibody responses
Roger D. Kouyos
1,2,15,16
*, Peter Rusert
1,15
, Claus Kadelka
1,2,15
, Michael Huber
1
, Alex Marzel
1,2
, Hanna Ebner
1
, Merle Schanz
1
,
Thomas Liechti
1,13
, Nikolas Friedrich
1
, Dominique L. Braun
1,2
, Alexandra U. Scherrer
1,2
, Jacqueline Weber
1
, Therese Uhr
1
,
Nicolas S. Baumann
1
, Christine Leemann
1,2
, Herbert Kuster
1,2
, Jean-Philippe Chave
3
, Matthias Cavassini
4
, Enos Bernasconi
5
,
Matthias Hoffmann
6
, Alexandra Calmy
7
, Manuel Battegay
8
, Andri Rauch
9
, Sabine Yerly
10
, Vincent Aubert
11
, Thomas Klimkait
12
,
Jürg Böni
1
, Karin J. Metzner
1,2
, Huldrych F. Günthard
1,2,16
*, Alexandra Trkola
1,16
* & The Swiss HIV Cohort Study
14
Understanding the determinants of broadly neutralizing antibody
(bNAb) evolution is crucial for the development of bNAb-based
HIV vaccines
1
. Despite emerging information on cofactors that
promote bNAb evolution in natural HIV-1 infections, in which the
induction of bNAbs is genuinely rare
2
, information on the impact of
the infecting virus strain on determining the breadth and specificity
of the antibody responses to HIV-1 is lacking. Here we analyse the
influence of viral antigens in shaping antibody responses in humans.
We call the ability of a virus strain to induce similar antibody
responses across different hosts its antibody-imprinting capacity,
which from an evolutionary biology perspective corresponds
to the viral heritability of the antibody responses. Analysis of 53
measured parameters of HIV-1-binding and neutralizing antibody
responses in a cohort of 303 HIV-1 transmission pairs (individuals
who harboured highly related HIV-1 strains and were putative direct
transmission partners or members of an HIV-1 transmission chain)
revealed that the effect of the infecting virus on the outcome of the
bNAb response is moderate in magnitude but highly significant.
We introduce the concept of bNAb-imprinting viruses and provide
evidence for the existence of such viruses in a systematic screening
of our cohort. The bNAb-imprinting capacity can be substantial, as
indicated by a transmission pair with highly similar HIV-1 antibody
responses and strong bNAb activity. Identification of viruses that
have bNAb-imprinting capacities and their characterization may
thus provide the potential to develop lead immunogens.
The capacity to evoke highly similar bNAb responses across vac-
cinees is crucial for an effective HIV-1 immunogen. Closely related
HIV-1 strains may induce similar neutralization responses, as observa-
tions from mother-to-child transmission suggest
3
. To formally evaluate
the virus-dictated heritability of antibody responses, we investigated
the imprinting capacity of HIV-1 antibody responses within transmis-
sion pairs. We designed our study to address two central problems
(Extended Data Fig. 1a, b). First, we investigated whether the same
virus, when transmitted to two different people, induces similar bind-
ing and neutralizing antibody responses (imprints a similar antibody
response). Second, we investigated how promising HIV-1 strains with
superior bNAb-imprinting capacity can be identified.
On the basis of the Swiss 4.5K Screen
4,5
, we established a large,
adult transmission-pair cohort (n = 303 putative transmission pairs)
with comprehensive information on HIV-1-binding and neutraliz-
ing antibody responses (Extended Data Fig. 1a). Extensive data on
HIV-binding antibody reactivity encompassing IgG1, IgG2 and IgG3
reactivity with 13 antigens was available for all 606 patients from pre-
vious analyses
5
(Supplementary Data 1). Neutralization activity was
assessed against a 14 multi-clade virus panel (Extended Data Fig. 2a
and Supplementary Data 1, 2) and evaluated by breadth and a cumu-
lative neutralization score, reflecting potency and breadth across the
analysed virus panel (Extended Data Fig. 2a–d). Overall, the neutraliza-
tion activity in the transmission pair cohort showed the typical pattern
seen in chronic infection
4
: the majority of patients displayed no or low
neutralization activity (73% of patients had below 10% breadth).
We hypothesized that if virus-associated factors are important in
determining antibody responses, HIV antibody response patterns
should be similar in transmission pairs. Using the established 53
HIV-1 antibody parameters (14 neutralization and 39 binding antibody
parameters), we conducted a systematic assessment of the HIV-1 anti-
body imprinting capacity in transmission pairs (Extended Data Fig. 2e).
We detected a significant, positive association of the transmitter and
recipient neutralization responses to 7 of the 14 panel viruses (Fig. 1a
and Extended Data Fig. 3a). The overall similarity of the neutraliza-
tion fingerprint within pairs across the 14 panel viruses was assessed
as average Spearman correlation (ρ
Spearman-average
) of their neutrali-
zation activity (Fig. 1b). To determine the statistical significance of
the observed similarity, we used shuffling approaches that randomly
reassign recipients to transmitters, thus generating a distribution for
the null-expectation of no association. Neutralization fingerprints in
observed transmission pairs proved on average positively and signifi-
cantly associated (ρ
Spearman-average
= 0.11, P
shuffling
< 0.001; Fig. 1b). To
confirm the influence of the infecting virus, we estimated the herita-
bility of antibody responses by two alternative methods adjusting for
the influence of various host, viral and disease factors that are known
to influence antibody responses
4,5
. First, we restricted the shuffling to
pairs with the same infection length, subtype and ethnicity (Fig. 1b).
Second, we considered mixed-effect Tobit models adjusted for key
drivers of HIV-1 antibody development (infection length, ethnicity,
virus load and viral diversity) and bNAb specificity (HIV-1 pol subtype)
(Fig. 1c). Both approaches confirmed a significant, within-pair corre-
lation of neutralization (Fig. 1b, c). Although other, not yet defined,
non-virus-associated factors common to both transmission partners
may exist, our data strongly suggest that the infecting virus strain affects
the development of neutralization responses. The effects (Fig. 1a, b)
remained robust when restricting the analysis to pairs infected with
subtype B virus, indicating that the effect is not driven by specific sub-
types (Extended Data Fig. 4a, b).
1
Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
2
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich,
Switzerland.
3
Clinique de La Source, Lausanne, Switzerland.
4
Division of Infectious Diseases, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland.
5
Division of Infectious
Diseases, Regional Hospital Lugano, Lugano, Switzerland.
6
Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
7
Division of Infectious Diseases, University Hospital
Geneva, University of Geneva, Geneva, Switzerland.
8
Division of Infectious Diseases, University Hospital Basel, University of Basel, Basel, Switzerland.
9
Department of Infectious Diseases, University
Hospital Bern, University of Bern, Bern, Switzerland.
10
Laboratory of Virology, Division of Infectious Diseases, University Hospital Geneva, University of Geneva, Geneva, Switzerland.
11
Division
of Immunology and Allergy, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland.
12
Division of Infection Diagnostics, Department of Biomedicine-Petersplatz, University
of Basel, Basel, Switzerland.
13
Present address: ImmunoTechnology Section, Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USA.
14
A list of participants and their
affiliations appears at the end of the paper.
15
These authors contributed equally: Roger D. Kouyos, Peter Rusert, Claus Kadelka.
16
These authors jointly supervised this work: Roger D. Kouyos,
Huldrych F. Günthard, Alexandra Trkola.
*
email:roger.kouyos@usz.ch; huldrych.guenthard@usz.ch; trkola.alexandra@virology.uzh.ch
406 | NATURE | VOL 561 | 20 SEPTEMBER 2018
© 2018 Springer Nature Limited. All rights reserved.